2021年11月23日

韩国健康AI公司忙着开发全球市场바로가기기자명金正日Chan-hyuk韩国健康人工智能解决方案提供商加速进入外国市场的努力。深生物周二表示,该公司与一家公司达成了战略合作伙伴关系在欧洲,另一个在印度提高竞争力DeepDx前列腺癌、前列腺癌诊断辅助软件,和在国际市场销售产品。Lunit的乳腺癌检测产品,Lunit洞察力CXR MMG,最近获得了FDA的批准。更具体地说,深生物将与巴黎TRIBVN医疗和印度Morphle实验室。根据深生物,TRIBVN医疗世界各地提供数字病理的解决方案。深生物预计DeepDx前列腺可以创建一个协同效应结合CaloPix时,TRIBVN医疗的主要解决方案,帮助各种癌症的诊断。Morphle实验室是一个数字病理幻灯片扫描仪制造商。该公司正在成为未来公司从Y Combinator获得投资后,美国启动加速器。Morphle实验室的扫描仪相比相对较小的通用数字病理笨重且昂贵的扫描仪。深生物也为海外市场研究与外国公司合作。 With HealthCare Konnect (HCK), a Swiss medical device distributor, Deep Bio analyzes medical AI markets in Europe and Africa to advance into those markets. Deep Bio aims to expand the geographic influence of DeepDx Prostate on pathology diagnosis institutions in Switzerland, Morocco, Algeria, Tunisia, and Egypt, the company said. “We are expanding our presence in the global market by introducing our innovative digital pathology software through close collaboration with companies in various countries,” said Kim Sun-woo, CEO of Deep Bio. Deep Bio will continue to seek active partnerships with foreign companies to expand the use of DeepDx Prostate, which provides faster and more consistent analysis results, and do its best to improve the global prostate cancer pathology diagnosis environment, Kim added. Lunit, another Korean health AI solution company, is also getting ready to expand the business into the global market. Earlier this month, Lunit scored the FDA approval for AI-backed imaging analysis solution Lunit Insight CXR Triage and a breast cancer detection product Lunit Insight CXR MMG. The company recently appointed Ken Nesmith as a chief business officer (CBO) of Lunit SCOPE, Marcus Skovhus as vice president of corporate development, and Park Su-bok as director of clinical strategy at Lunit INSIGHT. The new executives are expected to establish a long-term plan, regulation responses, and business strategies. “In the short term, we will work with overseas medical device companies to raise sales of diagnostic AI solutions. In the long term, we will discover and sell biomarkers in the treatment field,” a Lunit official said. “We will establish detailed strategies for entry into the global markets with foreign experts that we recently scouted.”